Molecular differences in Alzheimer's disease between male and female patients determined by integrative network analysis
Open accessAbstract
Alzheimer's disease ( AD ) is a complex neurodegenerative disease and the most common cause of dementia among the elderly. There has been increasing recognition of sex differences in AD prevalence, clinical manifestation, disease course and prognosis. However, there have been few studies on the molecular mechanism underlying these differences. To address this issue, we carried out global gene expression and integrative network analyses based on expression profiles ( GSE 84422) across 17 cortical regions of 125 individuals with AD . There were few genes that were differentially expressed across the 17 regions between the two sexes, with only four (encoding glutamate metabotropic receptor 2, oestrogen‐related receptor beta, kinesin family member 26B, and aspartoacylase) that were differentially expressed in three regions. A pan‐cortical brain region co‐expression network analysis identified pathways and genes (eg, glycogen synthase kinase 3β) that were significantly associated with clinical characteristics of AD (such as neurofibrillary score) in males only. Similarity analyses between region‐specific networks indicated that male patients exhibited greater variability, especially in the superior parietal lobule, dorsolateral prefrontal cortex and occipital visual cortex. A network module analysis revealed an association between clinical traits and crosstalk of sex‐specific modules. An examination of temporal and spatial patterns of sex differences in AD showed that molecular networks were more conserved in females than in males in different cortical regions and at different AD stages. These findings provide insight into critical molecular pathways governing sex differences in AD pathology.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Estrogen-related receptor beta is differentially expressed between male and female AD across four brain regions.
“For instance, estrogen‐related receptor beta was found to be differentially expressed between male and female AD across four brain regions.”
From Unraveling sex differences in Alzheimer's disease and related endophenotypes with brain proteomes (2025) · cites this paper as [15]
Transcriptome-wide sex differences in AD have been characterized in multiple studies.
“While transcriptome‐wide sex differences in AD have been characterized in multiple studies, 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 proteome‐wide sex differences in AD remain underexplored.”
From Unraveling sex differences in Alzheimer's disease and related endophenotypes with brain proteomes (2025) · cites this paper as [15]
Our results corroborate previous studies that highlighted a sex-specific association between AD and estrogen receptors.
“Our results corroborate previous studies that highlighted a sex‐specific association between AD and estrogen receptors. 15 , 16”
From Unraveling sex differences in Alzheimer's disease and related endophenotypes with brain proteomes (2025) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Neuroprotective effects of estrogens: potential mechanisms of action
Green, P. S., & Simpkins, J. W. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00017-4 · Cited by 523 · see citing works
Sex differences in visuo-spatial processing: An fMRI study of mental rotation
Hugdahl, K., Thomsen, T., & Ersland, L. (2006) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2006.01.026 · Cited by 368 · cited 1× · see citing works
“Furthermore, these three regions showed greater differences between males and females (Figure 4A), suggesting that they contribute to the observed sex differences in AD.(34,35) 3.”
Sex and Gender Differences in Alzheimer's Disease: Recommendations for Future Research
Carter, C. L., Resnick, E. M., Mallampalli, M., & Kalbarczyk, A. (2012) · Journal of Women's Health · doi:10.1089/jwh.2012.3789 · Cited by 231 · see citing works
Sex and gender differences in the causes of dementia: A narrative review
Rocca, W. A., Mielke, M. M., Vemuri, P., & Miller, V. M. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.008 · Cited by 186 · see citing works
Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition
Filon, J. R., Intorcia, A. J., Sue, L. I., Vazquez Arreola, E., Wilson, J., Davis, K. J., Sabbagh, M. N., Belden, C. M., Caselli, R. J., Adler, C. H., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw047 · Cited by 143 · cited 2× · see citing works
“Sexual dimorphism in brain structure and function also contributes to sex differences in AD.(5,7) Genetic studies on the association between single‐nucleotide polymorphisms and AD have suggested that the risk of AD is greater in female than in male carriers of the apolipoprotein (Apo)E4 allele.”
Gender and age modify the association between APOE and AD-related neuropathology
Ghebremedhin, E., Schultz, C., Thal, D. R., Rüb, U., Ohm, T. G., Braak, E., & Braak, H. (2001) · Neurology · doi:10.1212/wnl.56.12.1696 · Cited by 108 · see citing works
Flagged first, then by citations
Research works printed but not linked: 38
- [1]Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci. 2016; 18: 437‐ 446. 28179815 PMC5286729
- [2]Wang M, Roussos P, McKenzie A, et al. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. Genome Med. 2016; 8: 104. 27799057 PMC5088659
- [3]Stamatelopoulos K, Sibbing D, Rallidis LS, et al. Amyloid‐beta (1‐40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol. 2015; 65: 904‐ 916. 25744007
- [4]Heun R. Does gender play a role in Alzheimer therapy? Expert Rev Neurother. 2002; 2: 589‐ 591. 19810972
- [6]Kim S, Kim MJ, Kim S, et al. Gender differences in risk factors for transition from mild cognitive impairment to Alzheimer's disease: a CREDOS study. Compr Psychiatry. 2015; 62: 114‐ 122. 26343475
- [8]Corder EH, Ghebremedhin E, Taylor MG, et al. The biphasic relationship between regional brain senile plaque and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism. Ann N Y Acad Sci. 2004; 1019: 24‐ 28. 15246987
- [9]Fleisher A, Grundman M, Jack CR Jr, et al. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005; 62: 953‐ 957. 15956166
- [10]Damoiseaux JS, Seeley WW, Zhou J, et al. Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci. 2012; 32: 8254‐ 8262. 22699906 PMC3394933
- [11]Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology. 1998; 50: 669‐ 677. 9521254
- [13]Siegel BV Jr, Shihabuddin L, Buchsbaum MS, Starr A, Haier RJ, Valladares Neto DC. Gender differences in cortical glucose metabolism in Alzheimer's disease and normal aging. J Neuropsy Clin Neurosci. 1996; 8: 211‐ 214. 9081560
- [16]Behl C, Skutella T, Lezoualc'h F, et al. Neuroprotection against oxidative stress by estrogens: structure‐activity relationship. Mol Pharmacol. 1997; 51: 535‐ 541. 9106616
- [17]Davidson S, Golden JP, Copits BA, et al. Group II mGluRs suppress hyperexcitability in mouse and human nociceptors. Pain. 2016; 157: 2081‐ 2088. 27218869 PMC4988887
- [18]El Moustaine D, Granier S, Doumazane E, et al. Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G‐protein coupling. Proc Natl Acad Sci USA. 2012; 109: 16342‐ 16347. 22988116 PMC3479612
- [19]Kim SH, Steele JW, Lee SW, et al. Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Abeta oligomer mouse. Mol Psychiatry. 2014; 19: 1235‐ 1242. 25113378 PMC4217144
- [20]Caraci F, Molinaro G, Battaglia G, et al. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta‐amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol Pharmacol. 2011; 79: 618‐ 626. 21159998
- [21]Sommer A, Sass JO. Expression of aspartoacylase (ASPA) and Canavan disease. Gene. 2012; 505: 206‐ 210. 22750302
- [22]Wijayasinghe YS, Pavlovsky AG, Viola RE. Aspartoacylase catalytic deficiency as the cause of Canavan disease: a structural perspective. Biochemistry. 2014; 53: 4970‐ 4978. 25003821
- [23]Zaroff S, Leone P, Markov V, Francis JS. Transcriptional regulation of N‐acetylaspartate metabolism in the 5xFAD model of Alzheimer's disease: evidence for neuron‐glia communication during energetic crisis. Mol Cell Neurosci. 2015; 65: 143‐ 152. 25766789 PMC4393791
- [24]Yue X, Lu M, Lancaster T, et al. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci USA. 2005; 102: 19198‐ 19203. 16365303 PMC1323154
- [25]Li R, Singh M. Sex differences in cognitive impairment and Alzheimer's disease. Front Neuroendocrinol. 2014; 35: 385‐ 403. 24434111 PMC4087048
- [26]Andersson RH, Johnston A, Herman PA, et al. Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. Proc Natl Acad Sci USA. 2012; 109: 13118‐ 13123. 22822214 PMC3420189
- [27]Hu X, Hou H, Bastian C, et al. BACE1 regulates the proliferation and cellular functions of Schwann cells. Glia. 2017; 65: 712‐ 726. 28191691 PMC5357169
- [28]Makino C, Shibata H, Ninomiya H, Tashiro N, Fukumaki Y. Identification of single‐nucleotide polymorphisms in the human N‐methyl‐D‐aspartate receptor subunit NR2D gene, GRIN2D, and association study with schizophrenia. Psychiatr Genet. 2005; 15: 215‐ 221. 16094258
- [29]Yang SH, Perez E, Cutright J, et al. Testosterone increases neurotoxicity of glutamate in vitro and ischemia‐reperfusion injury in an animal model. J Appl Physiol. 2002; 92: 195‐ 201. 11744660
- [30]Llorens‐Martin M, Jurado J, Hernandez F, Avila J. GSK‐3beta, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014; 7: 46. 24904272 PMC4033045
- [31]Baum L, Hansen L, Masliah E, Saitoh T. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Mol Chem Neuropathol. 1996; 29: 253‐ 261. 8971700
- [32]Konhilas JP, Maass AH, Luckey SW, Stauffer BL, Olson EN, Leinwand LA. Sex modifies exercise and cardiac adaptation in mice. Am J Physiol Heart Circ Physiol. 2004; 287: H2768‐ H2776. 15319208 PMC2637113
- [33]Bertrand J, Despeaux M, Joly S, et al. Sex differences in the GSK3beta‐mediated survival of adherent leukemic progenitors. Oncogene. 2012; 31: 694‐ 705. 21725365
- [35]Jordan K, Wustenberg T, Heinze HJ, Peters M, Jancke L. Women and men exhibit different cortical activation patterns during mental rotation tasks. Neuropsychologia. 2002; 40: 2397‐ 2408. 12417468
- [36]Oti M, Brunner HG. The modular nature of genetic diseases. Clin Genet. 2007; 71: 1‐ 11. 17204041
- [37]Adamcsek B, Palla G, Farkas IJ, Derenyi I, Vicsek T. CFinder: locating cliques and overlapping modules in biological networks. Bioinformatics. 2006; 22: 1021‐ 1023. 16473872
- [38]Alfred T, Ben‐Shlomo Y, Cooper R, et al. Associations between APOE and low‐density lipoprotein cholesterol genotypes and cognitive and physical capability: the HALCyon programme. Age. 2014; 36: 9673. 25073452 PMC4150901
- [39]Rapoport SI. Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease. Neurotox Res. 2003; 5: 385‐ 398. 14715441
- [40]Tsai CF, Hung CW, Lirng JF, Wang SJ, Fuh JL. Differences in brain metabolism associated with agitation and depression in Alzheimer's disease. East Asian Arch Psychiatry. 2013; 23: 86‐ 90. 24088401
- [41]Lee JH, Jiang Y, Han DH, Shin SK, Choi WH, Lee MJ. Targeting estrogen receptors for the treatment of Alzheimer's disease. Mol Neurobiol. 2014; 49: 39‐ 49. 23771838
- [42]Coffey CE, Lucke JF, Saxton JA, et al. Sex differences in brain aging: a quantitative magnetic resonance imaging study. Arch Neurol. 1998; 55: 169‐ 179. 9482358
- [43]Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature. 2009; 461: 218‐ 223. 19741703
- [44]Goodenough S, Schleusner D, Pietrzik C, Skutella T, Behl C. Glycogen synthase kinase 3beta links neuroprotection by 17beta‐estradiol to key Alzheimer processes. Neuroscience. 2005; 132: 581‐ 589. 15837120
Cited by
Sorted by citations
Using machine intelligence to uncover Alzheimer’s disease progression heterogeneity
Qorri, B., Tsay, M., Agrawal, A., Au, R., & Gracie, J. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00026 · Cited by 13 · see citing works
Unraveling sex differences in Alzheimer's disease and related endophenotypes with brain proteomes
Mei, Z., Liu, J., Bennett, D. A., Seyfried, N., Wingo, A. P., & Wingo, T. S. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70206 · Cited by 11 · see citing works
- Authors
- Sun, L., Yang, S., Sun, H., Li, W., & Duan, S.
- Affiliations
- Department of Neurology The First Affiliated Hospital of Harbin Medical University Harbin China
- Department of Critical Care Medicine The First Affiliated Hospital of Harbin Medical University Harbin China
- Harbin Medical University (CN)
- First Affiliated Hospital of Harbin Medical University (CN)
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2018-11-05
- Volume
- 23
- Issue
- 1
- Pages
- 47-58
- ISSN
- 1582-1838 (ISSN-L)
- 1582-4934
- PMC
- PMC6307813
- OpenAlex
- W2900143604
- Cited by
- 32
- References
- 6
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 8 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 4
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Cellular and Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- Alzheimer's disease, sex differences, sex-specific gene expression, cortical regions, co-expression network, glycogen synthase kinase-3β, neurofibrillary tangles, aspartoacylase, disease stage, clinical traits
- MeSH terms
- Alzheimer Disease, Brain, Female, Humans, Male, Occipital Lobe, Sex Factors, Visual Cortex, Prefrontal Cortex, Gene Expression Profiling, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review